Micro
Aftermath
Active
Harga target Jabil Inc dinaikkan
Aktivitas menurun — narasi kehilangan relevansi.
Skor
0,2
Kecepatan
▲ 0,0
Artikel
6
Sumber
2
Penggerak Teratas
⚡ Sinyal Aktif:JBL
Linimasa Sentimen
Performa Sektor
Kinerja Saham
Linimasa Peristiwa
Artikel Terkait
Baird Raises its Price Target on Jabil (JBL)
Yahoo Finance
·
Jun 22, 2026
Analyst Report: Jabil Inc
Yahoo Finance
·
Jun 18, 2026
Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16
Yahoo Finance
·
Mar 22, 2026
Advanced Energy Industries Reaches Analyst Target Price
Nasdaq
·
Mar 20, 2026
Penggerak Teratas
| Ticker | Sektor | Perubahan |
|---|---|---|
| Industrials | +28,6% | |
| Healthcare | -20,1% | |
| Industrials | -5,0% |
⚡ Sinyal Aktif:JBL
🤖
Ringkasan AI
What happened: Argus, a financial analyst firm, raised its target price for Jabil Inc. (JBL) to $475 on June 18, 2026, marking a significant increase from its previous target of $300 set in March 2026. This revision comes amidst positive developments in the EMS industry and Jabil's performance. Additionally, shares of Advanced Energy Industries (AEIS) and CytomX Therapeutics (CTMX) crossed their respective analyst target prices of $93.25 and $16, indicating potential upside for these stocks.
Market impact: The positive target price revisions for JBL, AEIS, and CTMX signal a bullish sentiment in the EMS and healthcare sectors. This could drive investment flows into these companies and their peers, potentially leading to broader sector-wide gains. The revisions also suggest that analysts expect these companies to outperform their respective benchmarks, which could lead to valuation repricing and increased trading activity.
What to watch next: Investors should closely monitor Jabil's upcoming earnings release scheduled for August 4, 2026, to assess the company's performance and guidance. Additionally, any updates on CytomX's Phase 1 data for its lead asset Varseta-M could provide further catalysts for the stock. Lastly, investors should keep an eye on the broader EMS industry trends and any regulatory changes that may impact these companies.
Market impact: The positive target price revisions for JBL, AEIS, and CTMX signal a bullish sentiment in the EMS and healthcare sectors. This could drive investment flows into these companies and their peers, potentially leading to broader sector-wide gains. The revisions also suggest that analysts expect these companies to outperform their respective benchmarks, which could lead to valuation repricing and increased trading activity.
What to watch next: Investors should closely monitor Jabil's upcoming earnings release scheduled for August 4, 2026, to assess the company's performance and guidance. Additionally, any updates on CytomX's Phase 1 data for its lead asset Varseta-M could provide further catalysts for the stock. Lastly, investors should keep an eye on the broader EMS industry trends and any regulatory changes that may impact these companies.
Tinjauan AI per Jun 18, 2026
Lini Waktu
Pertama TerlihatMar 19, 2026
Terakhir DiperbaruiMar 19, 2026